Log In
BCIQ
Print this Print this
 

hetrombopag olamine

  Manage Alerts
Collapse Summary General Information
Company Jiangsu Hengrui Medicine Co. Ltd.
Description 
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationIdiopathic thrombocytopenic purpura (ITP)
Indication DetailsTreat idiopathic thrombocytopenic purpura (ITP)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today